Updated: January 26, 2026
How Does Insulin Glargine-Yfgn Work? Mechanism of Action Explained in Plain English
Author
Peter Daggett

Overview
How does insulin glargine-yfgn (Semglee) actually work in your body? This plain-English explainer covers the science of long-acting basal insulin and why it lasts 24 hours.
Is Insulin Glargine-Yfgn in stock near you?
Medfinder checks real pharmacy inventory — start a search and we'll find Insulin Glargine-Yfgn near you.
Insulin glargine-yfgn (formerly Semglee) is classified as a long-acting basal insulin analog. Understanding how it works can help you use it more effectively, understand why it's taken only once a day, and recognize what can affect its performance. This guide explains the science in terms anyone can understand.
First: Why Do People with Diabetes Need Insulin?
Insulin is a hormone produced by the beta cells in the pancreas. Its main job is to act as a 'key' that unlocks cells — particularly muscle and fat cells — so they can absorb glucose (sugar) from the bloodstream and use it for energy. Insulin also signals the liver to stop releasing stored glucose into the blood.
In Type 1 diabetes, the immune system destroys insulin-producing cells, so the body makes little or no insulin. In Type 2 diabetes, the pancreas still produces some insulin, but cells have become resistant to its effects, and over time the pancreas can't produce enough to compensate. In both cases, supplemental insulin is needed to control blood sugar.
Check live stock now.
How Insulin Glargine-Yfgn Differs from Human Insulin
Natural human insulin works quickly but doesn't last long. Insulin glargine-yfgn was engineered to provide a steady, low level of insulin over approximately 24 hours — mimicking the background (basal) insulin your pancreas would normally release throughout the day and night.
Two key structural changes were made to human insulin to create insulin glargine:
The amino acid asparagine at position A21 (on the A-chain) was replaced with glycine. This increases the molecule's stability.
Two arginine amino acids were added to the end of the B-chain. This shifts the molecule's isoelectric point, making it insoluble at the normal pH of body tissue.
The pH Trick: How It Stays in Your Body for 24 Hours
This is the clever part. The insulin glargine solution in the vial or pen is acidic (pH approximately 4). At this pH, it stays dissolved in liquid form. But when you inject it under your skin, it encounters the neutral pH of your body tissue (approximately pH 7.4).
At neutral pH, insulin glargine-yfgn precipitates — it forms tiny micro-crystals or deposits under the skin, creating what's called a 'depot.' From this depot, small amounts of insulin are slowly released into the bloodstream over approximately 24 hours. This produces a flat, peakless insulin profile — meaning it doesn't spike like rapid-acting insulins do. A steady, predictable background insulin level is the goal.
What Does Insulin Glargine-Yfgn Do Once It Reaches the Bloodstream?
Once the insulin reaches the bloodstream and binds to insulin receptors on cells, it triggers several important effects:
Promotes glucose uptake: Signals muscle and fat cells to absorb glucose from the bloodstream for energy or storage.
Suppresses liver glucose output: Signals the liver to stop releasing stored glucose (glycogen) into the blood — a process called hepatic glucose production.
Inhibits fat breakdown: Suppresses lipolysis (breakdown of stored fat into fatty acids), which can contribute to high blood sugar and ketoacidosis when absent.
Promotes protein synthesis: Supports muscle building by facilitating amino acid uptake in muscle tissue.
Why Is It Called a 'Biosimilar'?
Insulin glargine-yfgn is a biosimilar of Lantus (insulin glargine). Biosimilars are biological products (made from living organisms) that are highly similar to an already-approved reference product, with no clinically meaningful differences in safety, purity, or potency. They're the biological equivalent of a generic drug, but because they're made from living cells rather than chemicals, exact replication is not possible — hence 'similar' rather than 'identical.'
The 'yfgn' suffix was added by the FDA to differentiate this specific biosimilar from other insulin glargine products, for pharmacovigilance purposes. In practice, its mechanism of action is the same as Lantus.
Factors That Can Affect How Well It Works
Injection site: Duration of action can vary depending on where you inject (abdomen vs. thigh). Blood supply and temperature at the site affect absorption speed.
Injection consistency: Injecting at the same time each day and rotating sites consistently helps maintain stable blood sugar levels.
Lipodystrophy: Injecting repeatedly into the same site can cause fatty tissue changes that alter insulin absorption unpredictably.
Other medications: Corticosteroids, some blood pressure medications, and other drugs can raise or lower blood sugar, affecting how much insulin glargine-yfgn you need.
For a full guide on uses and dosing, see: What Is Insulin Glargine-Yfgn? Uses, Dosage, and What You Need to Know. And if you're having trouble finding it at the pharmacy, medfinder can check which pharmacies near you have it in stock.
Frequently Asked Questions
Insulin glargine-yfgn is engineered to precipitate (form micro-deposits) when it encounters the neutral pH of body tissue after injection. This depot releases insulin slowly over approximately 24 hours. Regular human insulin, by contrast, dissolves quickly and is absorbed rapidly. The structural modifications to the amino acid chain give insulin glargine-yfgn this unique property.
No. One of the key advantages of insulin glargine-yfgn (and insulin glargine products generally) is a relatively flat, peakless action profile compared to NPH insulin or other long-acting insulins. This means it provides a steady background insulin level rather than a spike of activity, which reduces the risk of nocturnal hypoglycemia.
Insulin glargine-yfgn is acidic (pH ~4), while other insulins are near-neutral pH. Mixing them would change the pH of the solution, causing the glargine to precipitate in the syringe rather than after injection — making the mixture cloudy and unpredictable in its action. Always inject insulin glargine-yfgn separately.
Insulin glargine-yfgn is technically a biosimilar, not a generic. Generic drugs are chemically identical copies of brand-name drugs. Biosimilars are highly similar to reference biological products but are made through living cell systems, meaning exact replication isn't possible. Insulin glargine-yfgn has no clinically meaningful differences from Lantus and carries the FDA interchangeable designation.
Medfinder Editorial Standards
Medfinder's mission is to ensure every patient gets access to the medications they need. We are committed to providing trustworthy, evidence-based information to help you make informed health decisions.
Read our editorial standardsPatients searching for Insulin Glargine-Yfgn also looked for:
More about Insulin Glargine-Yfgn
38,224 have already found their meds with Medfinder.
Start your search today.
Your information is private and never shared.





